Acute bacterial rhinosinusitis (ABRS) and community-acquired pneumonia (CAP) are common
community-acquired respiratory tract infections and represent a significant burden
to the health care system. Streptococcus pneumoniae and Haemophilus influenzae are two of the most common bacterial causes of ABRS and CAP [
1
,
2
]. Pneumococcal resistance to commonly used antimicrobials among S pneumoniae has increased at an alarming rate, and current antimicrobial therapies need to be
tailored to combat this surge in resistance.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.Am J Respir Crit Care Med. 2001; 163: 1730-1754
- Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.Otolaryngol Head Neck Surg. 2004; 130: 1-45
- Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders.J Allergy Clin Immunol. 1999; 103: 408-414
- Trends in antimicrobial drug prescribing among office-based physicians in the United States.JAMA. 1995; 273: 214-219
Scott Levin Prescription Audit from Verispan. LLC. January–December 2002.
- Sinus and Allergy Health Partnership.Otolaryngol Head Neck Surg. 2000; 123: 5-31
- Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.Clin Infect Dis. 2000; 31: 347-382
- Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 1997; 46: 1-24
- Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.JAMA. 1996; 275: 134-141
- Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999–2000 respiratory surveillance program.Am J Med. 2001; 111 ([discussion 36S–8S]): 25S-29S
- Emergence of antibiotic resistance in upper and lower respiratory tract infections.Am J Manag Care. 1999; 5: S651-S661
- Streptococcus pneumoniae resistant to penicillin and chloramphenicol.Lancet. 1977; 2: 995-997
GlaxoSmithKline. Antibiotic treatment and resistance timeline. Available at: http://www.augmentin.com. Accessed August 2, 2002.
- Emergence of multiply resistant pneumococci.N Engl J Med. 1978; 299: 735-740
- Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin.G. J Pediatr. 1974; 85: 671-673
- Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995.Antimicrob Agents Chemother. 2001; 45: 1721-1729
- Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–98.Emerg Infect Dis. 1999; 5: 757-765
- Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.Antimicrob Agents Chemother. 1996; 40: 1208-1213
- Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979–1987. The Pneumococcal Surveillance Working Group.J Infect Dis. 1991; 163: 1273-1278
- Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000.Clin Infect Dis. 2002; 34: S4-S16
- The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.J Antimicrob Chemother. 2003; 52: 229-246
- Penicillin-binding protein-mediated resistance in pneumococci and staphylococci.J Infect Dis. 1999; 179: S353-S359
- Beta-lactamase inhibitors from laboratory to clinic.Clin Microbiol Rev. 1988; 1: 109-123
- Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.Clin Infect Dis. 1997; 24: S19-S45
- Drug-resistant Streptococcus pneumoniae: rational antibiotic choices.Am J Med. 1999; 106 ([discussion 48S–52S]): 19S-25S
- Haemophilus influenzae type B resistant to ampicillin. A report of two cases.JAMA. 1974; 229: 298-301
- Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.Antimicrob Agents Chemother. 1990; 34: 2075-2080
- Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.Antimicrob Agents Chemother. 1997; 41: 292-297
- Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative.Int J Antimicrob Agents. 2002; 19: 119-123
- Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study.Antimicrob Agents Chemother. 1999; 43: 2612-2623
- Haemophilus influenzae and Moraxellacatarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).Antimicrob Agents Chemother. 1999; 43: 385-389
- Penicillin-binding proteins in beta-lactam-resistant streptococcus pneumoniae.Microb Drug Resist. 1999; 5: 91-99
- Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.Clin Infect Dis. 1998; 26 ([quiz 11–2]): 1-10
- Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.N Engl J Med. 1999; 341: 233-239
- Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.J Antimicrob Chemother. 2001; 48: 659-665
- Macrolide resistance among invasive Streptococcus pneumoniae isolates.JAMA. 2001; 286: 1857-1862
- Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.Clin Infect Dis. 2001; 33: 483-488
- Resistance among Streptococcus pneumoniae: implications for drug selection.Clin Infect Dis. 2002; 34: 1613-1620
- The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.N Engl J Med. 1995; 333: 481-486
- Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.Clin Infect Dis. 2000; 31: 613-615
- Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.Clin Infect Dis. 2000; 31: 1008-1011
- Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.Clin Infect Dis. 2002; 35: 556-564
- Emergence of macrolide resistance during treatment of pneumococcal pneumonia.N Engl J Med. 2002; 346: 630-631
- Pneumococcal meningitis during therapy of otitis media with clarithromycin.Pediatr Infect Dis J. 1995; 14: 1104-1105
- Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.Chest. 2000; 118: 1839-1840
- Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med. 2000; 160: 1399-1408
- Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clin Infect Dis. 2003; 37: 1405-1433
- A prediction rule to identify low-risk patients with community-acquired pneumonia.N Engl J Med. 1997; 336: 243-250
Nicholson SC, Conetta BJ, Mayer HB. Difference in pathogens isolated from outpatients and inpatients with community-acquired pneumonia. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 17–20, 2000.
- Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.Clin Ther. 1997; 19: 936-953
- Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.Eur Respir J. 1995; 8: 1999-2007
- Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team.Chest. 1998; 113: 1201-1206
- The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection.Infect Dis Clin North Am. Sep 1998; 12 ([vii.]): 569-592
- The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.Clin Ther. 2001; 23: 578-584
- Research Triangle Park.GlaxoSmithKline, NC2002
- Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.Int J Antimicrob Agents. 2002; 20: 235-247
File T, Lode H, Kurz H, Crann R and the 600 Study Group. Comparative efficacy/safety of pharmacokinetically enhanced amoxicillin/clavulanate 200/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). Presented at the 99th International Conference of the American Thoracic Society. Seattle, Washington, May 16–21, 2003.
- The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.Int J Antimicrob Agents Aug. Aug 2002; 20: 119-129
Garau J, Twynholm M, Garcia-Mendez E. and the 557 study group. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg b.d. versus amoxicillin/clavulanate 875/125 mg t.d.s. in community-acquired pneumonia (CAP) [poster]. Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, April 24–27, 2002.
Article info
Footnotes
☆This work was supported by GlaxoSmithKline.
Identification
Copyright
© 2004 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
